Company / EPS (Diluted)
Spyre Therapeutics, Inc. EPS (Diluted) History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$25.02
FY2023
5-year range
-$25.02 / -$1.52
FY2019-FY2023
Trend
-1546.1%
vs FY2022
Sector context
#205 of 204
Health Care
What the data says
EPS (Diluted) changed -1546% YoY in FY2023, a notable deviation from the 5-year average annual change of -305%.
Based on SEC 10-K filings.
-25.02 in FY2023.
Declined from $-2.45 to $-25.02 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 204This company -$25.02 Sector average -$0.89
▼
-2723.2% below sector average
Key checks
Key Insights
- In FY2023, eps (diluted) decreased 1546.1% year-over-year.
- Ranks #205 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -$25.02 | -1546.1% |
| FY2022 | -$1.52 | +38.0% |
| FY2021 | -$2.45 | -15.0% |
| FY2020 | -$2.13 | -18.3% |
| FY2019 | -$1.80 | +18.9% |
| FY2018 | -$2.22 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026